Management ChangeAug 3, 2026, 08:33 AM
Cue Biopharma Appoints James M. Ahlers as Chief Financial Officer
AI Summary
Cue Biopharma, Inc. announced the appointment of James M. Ahlers as its new Chief Financial Officer, effective immediately. Mr. Ahlers brings over 25 years of financial leadership experience, including a long tenure as CFO of Intarcia Therapeutics, and will report directly to CEO Shao-Lee Lin. His appointment comes at a pivotal time for the company, following a recent IND submission for CUE-221 and anticipated Phase 2 data readout for its CSU program by the end of the quarter. As part of his compensation, Mr. Ahlers received inducement equity awards consisting of 51,000 stock options and 25,500 restricted stock units, vesting over four years.
Key Highlights
- Cue Biopharma appointed James M. Ahlers as Chief Financial Officer.
- Mr. Ahlers will report to President and CEO Shao-Lee Lin, M.D., Ph.D.
- He brings over 25 years of financial leadership experience, including nearly two decades as CFO of Intarcia Therapeutics.
- Mr. Ahlers received inducement equity awards: 51,000 stock options and 25,500 restricted stock units.
- The stock option has an exercise price of $30.40, based on the closing price on July 30, 2026.
- Both awards vest over four years, subject to continued employment.
- The company recently submitted an IND for CUE-221 and anticipates Phase 2 CSU data readout by quarter-end.
Price Impact
More from CUE